ConnectMed360

Overview

ConnectMed360 is a hub-services provider purpose-built for oncology, rare disease, and complex specialty launches, operating nationally licensed commercial and non-commercial pharmacies in all 50 states plus PR and Guam alongside the affiliated Onco360 oncology pharmacy network. Founded in 2020 as a sister brand to Onco360, ConnectMed360 sits under PharMerica and BrightSpring Health Services (NASDAQ: BTSG); BrightSpring IPO’d in January 2024 after being KKR + Walgreens Boots Alliance PE-backed.

ConnectMed360 is not a generalist transactional hub or a copay-only point solution. The platform is positioned for therapy areas where launch teams need integrated eSolutions (ePA, eBV, e-Income Verification), clinical-nursing support, real-time speed-to-therapy analytics, and a dispensing arm in the same operator — particularly oncology, rare disease, and orphan-drug launches that benefit from Onco360 infrastructure.

Hub Capability Model

The framework below standardizes how Rx Almanac evaluates hub-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, ConnectMed360 is evaluated as an oncology and rare-disease hub with affiliated Onco360 pharmacy infrastructure.

Capability	Buyer should compare	ConnectMed360 readout
Therapy initiation and enrollment intake	Digital and human intake, eConsent, missing-information resolution, provider/patient portals, and clean case creation.	Core intake workflow. Full-service PAP administration with e-Income Verification and enrollment automation; “day-one” FDA-approval launch capabilities tied to Onco360 oncology workflow.
Benefits verification and coverage triage	Medical/pharmacy benefit verification, eligibility checks, payer-policy lookup, coverage routing, and speed from referral to actionable case.	Core coverage workflow. eBV provides real-time insurance benefits investigation and coverage determination across commercial and medical benefit.
Prior authorization, appeals, and reimbursement casework	PA initiation, payer-specific forms, clinical documentation, appeals, denial management, and field reimbursement handoffs.	Core PA casework. Integrated ePA, eBV, and e-Income Verification eSolutions; oncology and rare-disease PA depth is the operating focus area.
Affordability, PAP, and copay operations	Copay, free-drug, bridge, foundation, income verification, PAP renewal, and gross-to-net sensitive affordability logic.	Core affordability operations. Full-service PAP administration with e-Income Verification; bridge and free-drug program expansion noted in 2026 BrightSpring positioning.
Patient engagement and adherence operations	Omnichannel reminders, clinical education, nursing or training escalation, persistence outreach, and patient-facing support quality.	Core engagement model. Clinical nursing and social-behavioral support programs sit alongside Onco360 clinical infrastructure; oncology and rare-disease nurse-led teach-and-train depth.
Fulfillment, specialty pharmacy, and distribution coordination	Routing to SPs, non-commercial dispensing, DTP shipment, sample/replacement product, 3PL, and cold-chain handoffs.	Core fulfillment handoff. Commercial and non-commercial dispensing via nationally licensed pharmacies in all 50 states, PR, and Guam; Onco360 oncology pharmacy and CareMed specialty pharmacy sit under the same BrightSpring umbrella.
Program reporting, integrations, and governance	Manufacturer dashboards, KPI reporting, CRM/EHR/API integrations, SLA governance, and operating visibility across vendors.	Reporting layer. Real-time patient-data dashboards with speed-to-therapy tracking; confirm cross-program reporting depth and integration with incumbent manufacturer CRM environments.

Buyer Fit

• Best-fit use case: Evaluate ConnectMed360 for oncology, rare-disease, and orphan-drug launches where Onco360 clinical infrastructure, integrated eSolutions, and 50-state dispensing should sit under one operator.
• Best-fit buyers: Pharma manufacturers and biotech launch teams in oncology and rare disease; biologic and specialty drug types; products where “day-one” FDA-approval launch capability and cross-functional integration with BrightSpring’s ~275 sales-force FTEs across 64 territories adds leverage.
• Less ideal fit: Generalist non-specialty launches, copay-only programs, or DTP-first digital pharmacy models where the broader BrightSpring sales-force overlay is not relevant.
• Commercial fit: Custom/RFP pricing with service levels, data feeds, launch timing, and governance defined in the statement of work; clarify which Onco360 / CareMed / PharMerica capabilities are bundled in the proposed scope.
• Commercial diligence: Therapy-area depth (oncology vs. rare disease vs. orphan), nurse-led clinical staffing model, division of labor between ConnectMed360 hub and Onco360 / CareMed dispensing, data feeds into manufacturer CRM, and surge plan for FDA-approval launches.

Differentiators

• Onco360 oncology pharmacy affiliation: Deep oncology and rare-disease specialization through Onco360, one of the largest independent oncology specialty pharmacies in the U.S.
• 50-state commercial and non-commercial pharmacy footprint: Nationally licensed dispensing across all 50 states plus PR and Guam supports both commercial and free-drug program operations.
• Integrated eSolutions stack: ePA, eBV, and e-Income Verification operate inside the same hub workflow rather than as separate vendor handoffs.
• Day-one FDA-approval launch capability: Cross-functional integration with BrightSpring’s ~275 sales-force FTEs across 64 territories supports launches that need infrastructure live on approval day.
• Real-time speed-to-therapy dashboards: Manufacturer program-performance visibility tied to time-to-therapy as the operating KPI.
• BrightSpring umbrella (NYSE: BTSG): Sister brands Onco360 and CareMed Specialty Pharmacy sit under the same parent; PharMerica corporate provides operational depth.

RFP Questions

• Which steps are performed by ConnectMed360 hub, by Onco360 / CareMed pharmacy, and by the manufacturer in the proposed scope?
• What median time-to-therapy, PA turnaround, and first-fill conversion metrics can be reported for oncology and rare-disease programs?
• How are benefit verification, PAP, copay, and adherence data reconciled into manufacturer dashboards in real time?
• What is the day-one FDA-approval launch playbook, including staffing, training, and BrightSpring sales-force coordination?
• How does the integrated eSolutions stack (ePA, eBV, e-Income Verification) cover payer types in the therapy area in scope?
• What rare-disease and orphan-drug program experience is documented post-NORD partnership?
• What launch-surge staffing, training, and bilingual coverage commitments are available in the first 90 days?

Recent Activity

• 2026-03 - BrightSpring positioning emphasized day-one FDA-approval launch capabilities, cross-functional integration with the parent’s ~275 sales-force FTEs across 64 territories, and bridge plus free-drug program expansion.
• 2026-02 - Named NORD (National Organization for Rare Disorders) Partner-Level supporter, formalizing rare-disease advocacy alignment.
• 2025 - Enhanced eSolutions platform with improved real-time dashboards for manufacturer program-performance visibility.
• 2024-2025 - Expanded hub-services capabilities to support an increasing number of rare-disease and orphan-drug launches, leveraging Onco360 specialty pharmacy infrastructure.
• 2024-01 - BrightSpring Health Services (parent) IPO completed (NASDAQ: BTSG).